Spots Global Cancer Trial Database for temodar
Every month we try and update this database with for temodar cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Usefulness of Therapy Monitoring by Means of [(18)F]Fluoroethyltyrosine-Positron Emission Tomography (FET-PET) in Glioblastoma Multiforme Patients | NCT01089868 | Glioblastoma Mu... | 18 Years - | Ludwig-Maximilians - University of Munich | ||
| Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma | NCT00365222 | Glioblastoma Gliosarcoma | Temozolomide | 70 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma | NCT00365222 | Glioblastoma Gliosarcoma | Temozolomide | 70 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM | NCT00597493 | Recurrent Gliob... | Sorafenib and T... | 18 Years - | Duke University | |
| Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors | NCT03660761 | Efficacy and Sa... | apatinib temodar | 18 Years - 70 Years | Shandong Cancer Hospital and Institute | |
| Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM | NCT00612989 | Glioblastoma Gliosarcoma | Temodar and O6-... | 18 Years - | Duke University | |
| Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme | NCT00050986 | Glioblastoma Mu... | Temozolomide R115777 | - | M.D. Anderson Cancer Center | |
| Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma | NCT00501891 | Glioblastoma Mu... | Bevacizumab Metronomic Temo... | 18 Years - | Duke University | |
| Radiation Boost for Newly Diagnosed Glioblastoma Multiforme | NCT00376103 | Glioblastoma Mu... | temozolomide Brachytherapy External Beam R... | 18 Years - | Methodist Healthcare | |
| Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas | NCT00612339 | Glioblastoma Gliosarcoma | Avastin and Tem... | 18 Years - | Duke University | |
| Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases | NCT00582075 | Cancer Brain Metastase... | temozolomide | 19 Years - | University of Alabama at Birmingham | |
| Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide | NCT00629343 | Soft Tissue Sar... Mesothelioma | Azacitidine In ... | 18 Years - | Columbia University | |
| A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma | NCT01067066 | Melanoma | TPI 287 Temodar (Temozo... | 15 Years - | M.D. Anderson Cancer Center | |
| Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide | NCT02991456 | Chemo-radiation... | Rolapitant Ondansetron | 18 Years - | Duke University | |
| Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors | NCT03660761 | Efficacy and Sa... | apatinib temodar | 18 Years - 70 Years | Shandong Cancer Hospital and Institute | |
| Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme | NCT00883298 | Recurrent Gliob... Recurrent Glios... | temozolomide an... | 18 Years - 83 Years | Center for Neurosciences, Tucson | |
| Radiation Boost for Newly Diagnosed Glioblastoma Multiforme | NCT00376103 | Glioblastoma Mu... | temozolomide Brachytherapy External Beam R... | 18 Years - | Methodist Healthcare | |
| Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide | NCT01450826 | Nausea Vomiting Glioma | aprepitant ondansetron | 18 Years - | Duke University | |
| Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan | NCT00613028 | Glioblastoma Gliosarcoma | Temo + Avastin VP-16 + Avastin | 18 Years - | Duke University | |
| Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas | NCT00610571 | Glioblastoma Gliosarcoma Anaplastic Astr... | Oral Topotecan ... | 18 Years - | Duke University | |
| Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan | NCT00613028 | Glioblastoma Gliosarcoma | Temo + Avastin VP-16 + Avastin | 18 Years - | Duke University | |
| Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) | NCT01110876 | Brain Cancer Glioblastoma Mu... | Vorinostat Erlotinib Temozolomide | 18 Years - | M.D. Anderson Cancer Center | |
| To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors | NCT01193140 | Solid Tumor Can... | veliparib Temozolomide | 18 Years - | Abbott | |
| FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma | NCT01089244 | Astrocytoma Oligoastrocytom... Oligodendroglio... | 18 Years - | Ludwig-Maximilians - University of Munich | ||
| Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors | NCT00165230 | Neuroendocrine ... | Thalidomide Temodar | 18 Years - | Dana-Farber Cancer Institute | |
| IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma | NCT00089427 | Glioblastoma Mu... Anaplastic Astr... Oligoastrocytom... | IL13-PE38QQR Surgery for pla... Radiation thera... Temozolomide wi... | 18 Years - | INSYS Therapeutics Inc | |
| Study of Temozolomide to Treat Newly Diagnosed Brain Metastases | NCT00717275 | Brain Metastase... | Temozolomide | 18 Years - | University of Florida | |
| Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma | NCT01260103 | Optic Nerve Gli... | Temozolomide ANP Therapy | 6 Months - 18 Years | Burzynski Research Institute | |
| Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide | NCT00616005 | Glioblastoma | Temodar and Iri... | 18 Years - | Duke University | |
| Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma | NCT00525525 | Glioblastoma Gliosarcoma | Bevacizumab Tarceva Temozolomide | 18 Years - | University of California, San Francisco | |
| Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas | NCT00610571 | Glioblastoma Gliosarcoma Anaplastic Astr... | Oral Topotecan ... | 18 Years - | Duke University | |
| Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma | NCT00613093 | Glioblastoma Mu... Anaplastic Glio... | Temodar and O6-... | 18 Years - | Duke University | |
| PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas | NCT00612651 | Gliosarcoma Glioblastoma Anaplastic Astr... | Temodar and SCH... | 18 Years - | Duke University | |
| FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma | NCT01089244 | Astrocytoma Oligoastrocytom... Oligodendroglio... | 18 Years - | Ludwig-Maximilians - University of Munich | ||
| 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients | NCT00504660 | Anaplastic Glio... Glioblastoma Mu... Brain Cancer | Capecitabine Celecoxib (Cele... Temozolomide Lomustine 6-Thioguanine | 12 Years - | M.D. Anderson Cancer Center | |
| Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma | NCT00970996 | Melanoma | Temozolomide Abraxane Cisplatin Interleukin-2 Interferon alph... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma | NCT00525525 | Glioblastoma Gliosarcoma | Bevacizumab Tarceva Temozolomide | 18 Years - | University of California, San Francisco | |
| A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma | NCT00272415 | Melanoma | INO-1001 temozolomide | 18 Years - | Genentech, Inc. | |
| Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients | NCT00527657 | Brain Neoplasms Melanoma | Lomustine Temozolomide Thalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| Biochemotherapy With Temozolomide for Metastatic Melanoma | NCT00505635 | Melanoma | Temozolomide Velban Cisplatin Interleukin-2 Intron-A Thalidomide | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme | NCT00979017 | Glioblastoma Mu... Gliosarcoma | Avastin Temozolomide Irinotecan | 18 Years - | Duke University | |
| Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM) | NCT01186406 | Glioblastoma Mu... Gliosarcoma | Gliadel Radiation Thera... Avastin Temodar | 18 Years - | Duke University | |
| Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma | NCT02942264 | Brain Tumor Astrocytoma Astroglioma Glioblastoma Gliosarcoma | Zotiraciclib (T... Temozolomide (T... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma | NCT00734864 | Glioblastoma Mu... Gliosarcoma Anaplastic Astr... Anaplastic Olig... Glioma | enzyme-inducing... enzyme-inducing... | 18 Years - | Duke University | |
| Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases | NCT00582075 | Cancer Brain Metastase... | temozolomide | 19 Years - | University of Alabama at Birmingham | |
| Aerosol L9-NC and Temozolomide in Ewing's Sarcoma | NCT00492141 | Ewing's Sarcoma | Temozolomide L9-NC | 10 Years - | M.D. Anderson Cancer Center | |
| Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma | NCT00734864 | Glioblastoma Mu... Gliosarcoma Anaplastic Astr... Anaplastic Olig... Glioma | enzyme-inducing... enzyme-inducing... | 18 Years - | Duke University | |
| Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System | NCT01048554 | Melanoma | Temozolomide Bevacizumab | 18 Years - 90 Years | Mt. Sinai Medical Center, Miami | |
| Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM | NCT00612989 | Glioblastoma Gliosarcoma | Temodar and O6-... | 18 Years - | Duke University | |
| Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas | NCT00612339 | Glioblastoma Gliosarcoma | Avastin and Tem... | 18 Years - | Duke University | |
| Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas | NCT00612339 | Glioblastoma Gliosarcoma | Avastin and Tem... | 18 Years - | Duke University | |
| Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM) | NCT01186406 | Glioblastoma Mu... Gliosarcoma | Gliadel Radiation Thera... Avastin Temodar | 18 Years - | Duke University | |
| Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer | NCT01506609 | Metastatic Brea... | Placebo Veliparib Carboplatin Temozolomide Paclitaxel | 18 Years - | AbbVie | |
| Dietary Methionine Restriction Plus Temozolomide for Recurrent GBM | NCT00508456 | Glioblastoma Mu... | Temodar (Temozo... Hominex-2 | - | M.D. Anderson Cancer Center | |
| Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme | NCT00883298 | Recurrent Gliob... Recurrent Glios... | temozolomide an... | 18 Years - 83 Years | Center for Neurosciences, Tucson | |
| A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients | NCT00526617 | Non-hematologic... Metastatic Mela... Breast Cancer Ovarian Cancer Primary Periton... Fallopian Tube ... Hepatocellular ... | ABT-888 Temozolomide | 18 Years - | AbbVie | |
| Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide | NCT01450826 | Nausea Vomiting Glioma | aprepitant ondansetron | 18 Years - | Duke University | |
| Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide | NCT00629343 | Soft Tissue Sar... Mesothelioma | Azacitidine In ... | 18 Years - | Columbia University | |
| Dose-Intense Temozolomide in Recurrent Glioblastoma | NCT00657267 | Glioblastoma Gliosarcoma | Temozolomide | 18 Years - | Dana-Farber Cancer Institute | |
| Biochemotherapy With Temozolomide for Metastatic Melanoma | NCT00505635 | Melanoma | Temozolomide Velban Cisplatin Interleukin-2 Intron-A Thalidomide | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma | NCT01067066 | Melanoma | TPI 287 Temodar (Temozo... | 15 Years - | M.D. Anderson Cancer Center | |
| Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM) | NCT00555399 | Glioblastoma Mu... Anaplastic Glio... | Vorinostat Isotretinoin Surgical Resect... Temozolomide | 18 Years - | M.D. Anderson Cancer Center | |
| Medical Treatment of "High-Risk" Neurofibromas | NCT00846430 | Neurofibromatos... | Peg-Interferon ... Celecoxib (Cele... Temozolomide (t... Vincristine Sul... | 2 Years - 30 Years | Spectrum Health Hospitals | |
| Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme | NCT00050986 | Glioblastoma Mu... | Temozolomide R115777 | - | M.D. Anderson Cancer Center | |
| Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors | NCT00165230 | Neuroendocrine ... | Thalidomide Temodar | 18 Years - | Dana-Farber Cancer Institute | |
| Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma | NCT01260103 | Optic Nerve Gli... | Temozolomide ANP Therapy | 6 Months - 18 Years | Burzynski Research Institute | |
| Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma | NCT00895960 | Glioblastoma CNS Disease Brain Diseases | Dasatinib RT (Radiotherap... TMZ (Temozolomi... | 18 Years - | M.D. Anderson Cancer Center | |
| Doxycycline, Temozolomide and Ipilimumab in Melanoma | NCT01590082 | Melanoma | Doxycycline Ipilimumab Temozolomide | 18 Years - | M.D. Anderson Cancer Center | |
| Medical Treatment of "High-Risk" Neurofibromas | NCT00846430 | Neurofibromatos... | Peg-Interferon ... Celecoxib (Cele... Temozolomide (t... Vincristine Sul... | 2 Years - 30 Years | Spectrum Health Hospitals | |
| Taxotere/Temodar/Cisplatin Study in Melanoma Patients | NCT00527761 | Metastatic Mela... | Cisplatin Docetaxel Temodar | 18 Years - | M.D. Anderson Cancer Center | |
| Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System | NCT01048554 | Melanoma | Temozolomide Bevacizumab | 18 Years - 90 Years | Mt. Sinai Medical Center, Miami | |
| Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients | NCT00525031 | Melanoma | Temozolomide (T... Pegylated Inter... | 18 Years - | M.D. Anderson Cancer Center | |
| Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma | NCT00970996 | Melanoma | Temozolomide Abraxane Cisplatin Interleukin-2 Interferon alph... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide | NCT00616005 | Glioblastoma | Temodar and Iri... | 18 Years - | Duke University | |
| Study of Temzolomide and Gleevec in Advanced Melanoma | NCT00667953 | Melanoma Advanced Melano... | Gleevec Temodar | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma | NCT01409174 | Melanoma | Ipilimumab Temozolomide Cisplatin Interferon Alfa... Interleukin-2 | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma | NCT00734864 | Glioblastoma Mu... Gliosarcoma Anaplastic Astr... Anaplastic Olig... Glioma | enzyme-inducing... enzyme-inducing... | 18 Years - | Duke University | |
| To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors | NCT01193140 | Solid Tumor Can... | veliparib Temozolomide | 18 Years - | Abbott | |
| DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis | NCT00515788 | Neoplastic Meni... | DepoCyt Temozolomide | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
